Display Settings:

Format

Send to:

Choose Destination
    Curr Opin Investig Drugs. 2003 Jan;4(1):60-5.

    Tadalafil Lilly ICOS.

    Source

    Bristol-Myers Squibb Company, Hopewell Discovery Chemistry, Princeton, NJ 08543-5400, USA. david.rotella@bms.com

    Abstract

    Tadalafil is a phosphodiesterase type 5 inhibitor in development by Lilly ICOS for the potential treatment of erectile dysfunction. The compound will be marketed in North America and Europe by a collaboration formed by Eli Lilly & Co and ICOS Corp. Eli Lilly & Co has marketing rights in all other territories. Marketing approval in Europe was granted in November 2002, with launch expected in the first half of 2003. An approvable letter was issued by the FDA in April 2002, with a US launch anticipated in the first half of 2003.

    PMID:
    12625031
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk